Fig. 2: Sialokinin reduces activation and CHIKV infection in primary human myeloid cells.

Human monocytes and monocyte-derived macrophages (MDMs) from ten healthy donors were infected with CHIKV in the presence or absence of sialokinin (10 μM). a Activation profiles of monocytes and MDMs were assessed by flow cytometry, focusing on CD169 expression. Sialokinin treatment significantly reduced CD169 expression was lower in both monocytes and MDMs following CHIKV infection (MOI = 10) at 24 (monocytes) or 48 (MDMs) hours post-infection. b CHIKV infection was determined using FACS analysis and qRT-PCR on the viral supernatant. Viral load was quantified by qRT-PCR targeting CHIKV nsP1 viral copies. Data were log₁₀-transformed prior to statistical analysis. CHIKV infectivity toward monocytes and MDMs was reduced in the presence of sialokinin. Statistical analyses were performed using either a paired two-tailed t-test or a Wilcoxon signed-rank test, depending on data distribution.